在眼皮表面炎症性疾病中,免疫调节剂治疗的最新进展
Ali Khodor1, Luis A Rodriguez-Gutierrez, Raul E Ruiz-Lozano
1Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA.
Current opinion in ophthalmology
|April 25, 2025
概括
新型免疫调节疗法为眼表表面炎症疾病提供了前景良好的皮质类固醇替代品. 向药物和生物药物正在推进对过敏结膜炎和oGVHD等疾病的治疗.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 眼表面炎症疾病 (OSID) 存在复杂的免疫挑战.
- 作为传统疗法的皮质类固醇有其局限性.
- 需要新的,节省类固醇的免疫调节选择.
研究的目的:
- 审查OSIDs的新型,类固醇节约性免疫调节治疗方法.
- 探索超越传统疗法 (如皮质类固醇) 的进展.
主要方法:
- 关于OSIDs免疫调节疗法的最新进展的文献综述.
- 对针对特定免疫路径的新兴药物的分析.
主要成果:
- 免疫调节疗法已经发展到包括JAK抑制剂 (例如,ruxolitinib) 和生物药物 (例如,dupilumab,upadacitinib).
- 雅克抑制剂和组合疗法对oGVHD有希望.
- 利图西马布和IVIg对膜炎的治疗有效.
- 新的目标包括化学激素受体阻断剂,Treg调节和微RNA疗法.
结论:
- 未来的OSID治疗涉及完善当前治疗方法和开发向生物药物.
- 这些进步旨在提高视力威胁眼部疾病的疗效和安全性.
更多相关视频
相关概念视频
Open Angle Glaucoma: Treatment
358
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
358
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80


